Dr Natalie Cook reports on recent ASCO meeting

June 26, 2024

The American Society of Clinical Oncology (ASCO) held its annual meeting in Chicago in June 2024. Although there was limited CUP research presented we wanted to highlight two studies presented as posters at this meeting: The UK CUPCOMP study was presented by Dr Alicia-Marie Conway, University of Manchester, Cancer Research UK National Biomarker Centre and The Christie NHS TRust (photo below); and the Australian SUPER study was presented by Dr Tharani Sivakumaran, University of Melbourne and Peter MacCallum Cancer Centre.

CUPCOMP was a multi-site non-randomised prospective feasibility clinical trial investigating tissue and liquid biomarkers in CUP. It compared the feasibility of molecular profiling from tissue and blood (using circulating tumour DNA or ctDNA) in patients diagnosed with CUP. ctDNA analysis was 93% successful and reliably concordant with tissue. Potentially actionable alterations were found in 64% of patients. It showed ctDNA molecular profiling should be considered as a reliable alternative, to tissue-based testing.

More info can be found here:  CUPCOMP: A multi-site UK trial in carcinoma of unknown primary: A comparison across tissue and liquid biomarkers. | Journal of Clinical Oncology (ascopubs.org)

← Back to blog